Drug intelligence / Profile preview

dapagliflozin + vildagliptin

Development stage: Unknown
Lead developer: Makkena venkata sai sandeep
Modality: Small Molecules
Administration: Oral

Overview

DAPAHEER-VG is an oral fixed-dose combination therapy containing the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin. It is developed by Maksun Biotech and is approved in India for the management of glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin works by reducing renal glucose reabsorption, thereby promoting urinary glucose excretion, while vildagliptin enhances insulin secretion and suppresses glucagon release by inhibiting the degradation of incretin hormones. Together, they provide a complementary mechanism of action to lower blood glucose levels.

Brand names: Acevilda DDAPAHEER-VGDAPAHEER-VG 100DAPAHEER-VG100DAPAHEER-VG-100Dapadax VGDaparyl VDapazol VDapagotfil VDapoflit VDgson VEndoflozin-VGluout VGluvilda DGlyduoInsuvilda DJalra DpTorglip DVarnglip DVicemic DVildacag DPVildadeg-DVildair- DVildalip-DVildamac DpVilingtin-DZViltrop DPViquglip-DZ-Vil-D
Other names: dapagliflozin and vildagliptindapagliflozin/vildagliptinvildagliptin + dapagliflozinvildagliptin and dapagliflozinvildagliptin/dapagliflozin

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)DPP-4 (Dipeptidyl Peptidase-IV)DPP8 (Dipeptidyl peptidase 8)SLC5A1 (Sodium Glucose Cotransporter 1)DPP9 (Dipeptidyl Peptidase 9)

Beyond the preview

Go deeper on dapagliflozin + vildagliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dapagliflozin + vildagliptin.

Explore the full profile